Table 2.
Epidermal Leukocytes in Rapamycin-treated TGF-β1 Null and Control Mice
| Group | Genotype (Age) | Treatment | LC (%) | DETC (%) | Leukocytes (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | −/− (39 d) | Rapamycin | 0 | 1.2 | 0.9 | |||||
| −/− (42 d) | Rapamycin | 0 | 0.8 | 0.7 | ||||||
| −/− (42 d) | Rapamycin | 0 | 0.6 | 0.4 | ||||||
| 2 | +/+ (39 d) | Rapamycin | 1.5 | 1.4 | 2.8 | |||||
| +/+ (42 d) | Rapamycin | 2.5 | 2.1 | 4.4 | ||||||
| 3 | +/+ (42 d) | Rapamycin | 0.8 | 0.9 | 1.7 | |||||
| +/+ (39 d) | None | 1.6 | 1.7 | 3.1 | ||||||
| +/− (42 d) | None | 2.6 | 3.4 | 4.8 |
Mice were treated with rapamycin (4 mg/kg i.p.) on postnatal day 10 and 3×/wk thereafter. Data represent percentages of viable cells expressing the indicated antigens in suspensions of cells derived from trunk epidermis of individual mice. Subpopulations of epidermal leukocytes were identified as described in the legend for Table 1.